1. Diabetes research update: GGC MCN meeting 5th February 2019
John R Petrie
Professor of Diabetic Medicine
University of Glasgow, UK

2. Disclosures Advisory and Consultancy Work:
Novo Nordisk, Sanofi-Aventis, Biocon, Astra Zeneca, Servier
Clinical trials committees:
ACI Clinical (Boehringer), Janssen, NovoNordisk, Quintiles (Genentech, Roche), Sanofi-Aventis
Recipient of donation of services to support Investigator-led research:
Merck (Germany), Itamar Medical (Israel), Astra Zeneca
Investigator-led research funding:
Janssen (RISC study)
Travel and accommodation support:
Novo Nordisk, Lilly
No stock in any pharmaceutical or technology company

3. Multicentre academic 3-year RCT of metformin in type 1 diabetes
23 centres international centres
Scotland
Glasgow
Dundee
Edinburgh
Aberdeen
Ayr
Denmark
(Steno)
Canada
London, Ontario
Ottawa, Ontario
England
Newcastle
Durham
Manchester
Hull
Aintree
London
Plymouth
Exeter
Gloucester
Bristol
Netherlands
(Maastricht)
Australia
Sydney
Melbourne
Chief Investigator: John Petrie (Glasgow)
Deputy: Helen Colhoun (Edinburgh) 3

6. Via clinical trials, epidemiology, translational studies and collaboration to:
(i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease
(ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease
(iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation
(iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

7. Via clinical trials, epidemiology, translational studies and collaboration to:
(i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease
(ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease
(iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation
(iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

9. Via clinical trials, epidemiology, translational studies and collaboration to:
(i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease
(ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease
(iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation
(iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

10. Scottish Diabetes Research Network 2005
(SDRN)

11. NHS Research Scotland Diabetes 2019 (NRSD or NRS Diabetes)
SDRN EPIDEMIOLOGY
Chair: Dr R Lindsay

13. Heart failure in diabetes (3.25 million)
Men
Women 50 40 30
Rate per 1000 person years 20 10 20 40 60 80 20 40 60 80
Figure 1: Age, sex and deprivation adjusted incidence of heart failure hospitalisation (95% CIs) by diabetes type, age and sex

14. Myocardial infarction
MEN
WOMEN
Diabetologia, 17th Jan 2019

15. Via clinical trials, epidemiology, translational studies and collaboration to:
(i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease
(ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease
(iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation
(iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

16. Gill JMR, Petrie JR, Sattar N, Gray S
Gill JMR, Petrie JR, Sattar N, Gray S. Mechanisms of insulin resistance in South Asians: role of muscle metabolism and microvascular perfusion.
Medical Research Council. £654,057 ( )

17. Via clinical trials, epidemiology, translational studies and collaboration to:
(i) discover the pathways and processes linking obesity and physical inactivity to cardiovascular and metabolic disease
(ii) understand the mechanisms underlying cardiovascular complications associated with diabetes, obesity, dyslipidaemia and renal disease
(iii) explore the implications for the wider population - including groups defined by ethnicity, gender and deprivation
(iv) use this knowledge to develop and target new therapies and lifestyle interventions to prevent and treat metabolic disease

19. Triple therapy in type 1 diabetes Insulin, GLP-1 and SGLT2i?
Dandona P*, Petrie JR (co-PIs), Ghanim H, Boyle J, Lindsay R, Ford I. Triple therapy for T1DM with insulin, semaglutide and dapagliflozin. JDRF Strategic Research Award. $1.64M ( )
*State University of New York (SUNY)

20. 70 registrations from NHS GGC last week!
John Kerr
Research Register Manager
70 registrations from NHS GGC
last week!
Mailed 1082 dafne attendees, Supplied leaflets to pharmacies as below,
potential for supplying leaflets to T2 education and possibly people with t2 early after dx,

22. Acknowledgements Thank you!
@johnrpetrie
@drjamesboyle
@MetaMedTeam